University of Texas: Targeting Menin Induces Responses In Acute Leukemias With KMT2A Rearrangements Or NPM1 Mutations
December 12, 2022
December 12, 2022
HOUSTON, Texas, Dec. 12 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Dec. 10, 2022:
* * *
MD Anderson presents updated results from AUGMENT-101 trial at ASH 2022
* * *
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with SNDX-5613, now named revumenib, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements o . . .
* * *
MD Anderson presents updated results from AUGMENT-101 trial at ASH 2022
* * *
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with SNDX-5613, now named revumenib, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements o . . .